Publicacións en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (14)

2022

  1. Detection of azole resistance in Aspergillus fumigatus complex isolates using MALDI-TOF mass spectrometry

    Clinical Microbiology and Infection, Vol. 28, Núm. 2, pp. 260-266

2021

  1. Azole and amphotericin B MIC values against aspergillus fumigatus: High agreement between spectrophotometric and visual readings using the EUCAST EDef 9.3.2 procedure

    Antimicrobial Agents and Chemotherapy, Vol. 65, Núm. 1

  2. Azole resistance survey on clinical Aspergillus fumigatus isolates in Spain

    Clinical Microbiology and Infection, Vol. 27, Núm. 8, pp. 1170.e1-1170.e7

  3. Persistent pulmonary hypertension in corrected valvular heart disease: Hemodynamic insights and long-term survival

    Journal of the American Heart Association, Vol. 10, Núm. 2, pp. 1-21

2018

  1. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: A multicenter, double-blind, randomized clinical trial

    European Heart Journal, Vol. 39, Núm. 15, pp. 1255-1264

2015

  1. Pulmonary hypertension and congenital heart disease: An insight from the REHAP national registry

    International Journal of Cardiology, Vol. 184, Núm. 1, pp. 717-723

2014

  1. Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011

    Antimicrobial Agents and Chemotherapy, Vol. 58, Núm. 3, pp. 1529-1537

  2. Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: Calcineurin-inhibitors conversion or minimization?

    International Journal of Cardiology, Vol. 171, Núm. 1, pp. 15-23

2013

  1. Differential clinical characteristics and prognosis of intraventricular conduction defects in patients with chronic heart failure

    European Journal of Heart Failure, Vol. 15, Núm. 8, pp. 877-884

  2. Rejection after conversion to a proliferation signal inhibitor in chronic heart transplantation

    Clinical Transplantation, Vol. 27, Núm. 6

2012

  1. Cost effectiveness of prostacyclins in pulmonary arterial hypertension

    Applied Health Economics and Health Policy, Vol. 10, Núm. 3, pp. 175-188

  2. Steroid Withdrawal during 5 years following heart transplantation, and the relationship between steroid dosage at 1-year follow-up and complications during the next 2 years: Results from the restco study

    Transplantation Proceedings

2008

  1. Standards of care in pulmonary hypertension

    Revista Espanola de Cardiologia, Vol. 61, Núm. 2, pp. 170-184

  2. Standards of care in pulmonary hypertension. Consensus statement of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Spanish Society of Cardiology (SEC)

    Archivos de Bronconeumologia, Vol. 44, Núm. 2, pp. 87-99